First AIA Review of Pharmaceutical Patents

Jun 26, 2014

Reading Time : 1 min

According to Ryan Davis’s Law360 article, "Merck Supplement Patents Nixed in 1st Pharma AIA Reviews," “only about 6 percent of the AIA petitions filed to date have challenged pharmaceutical patents,” making this possibly the “first inter partes review involving pharmaceuticalrelated patents.”

Gnosis S.P.A. v. South Alabama Medical Science Foundation, IPR201300116, IPR201300118 & IPR201300119 (PTAB June 20, 2014) [Kamholz (opinion); Bonilla; Snedden]; Gnosis, S.P.A. v. Merck & CIE, IPR20130017 (PTAB June 20, 2014) [Kamholz (opinion); Bonilla; Snedden].

Previous Entries

August 11, 2025

D. Mass.: Knowledge of Parent Patent, by Itself, May Not Suffice to Show Knowledge of Child Patent for Purposes of Indirect and Willful Infringement

August 8, 2025

District Court: Permanent Injunction Includes the Reassignment of Patent Applications Appropriate for Trade Secret Misappropriation

August 6, 2025

Patent Damages Based on Avoided Costs Do Not Invoke the Entire Market Value Rule

First AIA Review of Pharmaceutical Patents

Share This Insight

Categories

Previous Entries